362P Phase Ia Study to Evaluate GDC-6036 Monotherapy in Patients with Colorectal Cancer (CRC) with KRAS G12C Mutation

J. Desai, S-W. Han,M. D. Forster,T. W. Kim,G. Alonso Casal,E. Shacham Shmueli,S. E. Bowyer,M. J. De Miguel,A. Falcon Gonzalez,R. H. Jones,M. G. Krebs,W. H. Miller, L. Paz-Ares,P. Lorusso,A. Sacher,N. Dharia, M. T. Lin,J. L. Schutzman,Z. Shi,M. Patel

Annals of oncology（2022）

引用 4|浏览16

暂无评分

摘要

The oncogenic KRAS G12C mutation is found in ∼4% CRC patients (pts). GDC-6036 is an oral, highly potent and selective KRAS G12C inhibitor, with robust tumor growth inhibition in multiple preclinical models.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要